Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus chemotherapy as third-line treatment for EGFR-mutant NSCLC
ChiCTR2500107714Phase 4Not yet recruiting
- Sponsor
- Nantong Cancer Hospital
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of QL1706 in non-small cell lung cancer (NSCLC), sponsored by Nantong Cancer Hospital. Primary endpoints: Objective response rate and Adverse events. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500107714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107714.